| Autor: |
Lin, Li, Xue, Song, Chen, Jiaqi, Gu, Cuihong, Zhang, Jingzheng, Xing, Enhong, Wang, Wei, Wang, Lihong, Zhang, Zhihua |
| Předmět: |
|
| Zdroj: |
Leukemia & Lymphoma; Aug2024, Vol. 65 Issue 8, p1181-1185, 5p |
| Abstrakt: |
This article discusses a case study on the treatment of relapsed acute myeloid leukemia (AML) in an elderly patient with the AML1:ETO fusion gene. The patient achieved remission initially but relapsed a year later. Whole-exome sequencing revealed mutations in genes associated with DNA repair, suggesting a potential benefit from PARP inhibitor (PARPi) treatment. The patient received olaparib in combination with low-dose chemotherapy and achieved complete remission. In vitro experiments also showed the synergistic effect of olaparib and decitabine on AML1:ETO leukemia cell lines. The article suggests that this treatment approach may be promising for relapsed AML1:ETO-positive leukemia, particularly in elderly patients, but further clinical trials are needed for validation. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
